The effects of age on carbamazepine pharmacokinetics and adverse effects.
作者信息
Hockings N, Pall A, Moody J, Davidson A V, Davidson D L
出版信息
Br J Clin Pharmacol. 1986 Dec;22(6):725-8. doi: 10.1111/j.1365-2125.1986.tb02965.x.
Abstract
The pharmacokinetics and effect of single oral doses of carbamazepine (400 mg) were compared in a group of six young volunteers aged between 20 and 25 years, and a second group of five elderly volunteers aged between 66 and 84 years. No age related changes in salivary or plasma pharmacokinetics or in psychomotor function were detected.
摘要
相似文献
1
The effects of age on carbamazepine pharmacokinetics and adverse effects.
Br J Clin Pharmacol. 1986 Dec;22(6):725-8. doi: 10.1111/j.1365-2125.1986.tb02965.x.
2
Clinical, cognitive, and neurophysiologic correlates of short-term treatment with carbamazepine, oxcarbazepine, and levetiracetam in healthy volunteers.
Ann Pharmacother. 2004 Nov;38(11):1816-22. doi: 10.1345/aph.1E136. Epub 2004 Sep 14.
3
A study on carbamazepine levels, including estimation of 10-11 epoxy-carbamazepine and levels in free plasma and saliva.
Dev Med Child Neurol. 1986 Dec;28(6):713-8. doi: 10.1111/j.1469-8749.1986.tb03922.x.
4
Kinetics of carbamazepine and carbamazepine-epoxide, determined by use of plasma and saliva.
Clin Pharmacol Ther. 1978 Mar;23(3):320-8. doi: 10.1002/cpt1978233320.
5
Effects of oxcarbazepine and carbamazepine on driving ability: a double-blind, randomized crossover trial with healthy volunteers.
Psychopharmacology (Berl). 2010 May;210(1):53-63. doi: 10.1007/s00213-010-1814-y. Epub 2010 Mar 17.
6
Concentration-effect relationships with carbamazepine and its epoxide on psychomotor and cognitive function in epileptic patients.
J Neurol Neurosurg Psychiatry. 1988 Jul;51(7):929-33. doi: 10.1136/jnnp.51.7.929.
7
Clinical pharmacokinetics of carbamazepine.
Clin Pharmacokinet. 1978 Mar-Apr;3(2):128-43. doi: 10.2165/00003088-197803020-00003.
8
[Carbamazepine. A controlled clinical trial].
Ugeskr Laeger. 1980 Jun 2;142(23):1504-7.
9
Pharmacokinetics and pharmacodynamics of adinazolam and N-desmethyladinazolam after oral and intravenous dosing in healthy young and elderly volunteers.
J Clin Psychopharmacol. 1992 Dec;12(6):403-14.
10
The cognitive and psychomotor effects of remacemide and carbamazepine in newly diagnosed epilepsy.
Epilepsy Behav. 2009 Mar;14(3):522-8. doi: 10.1016/j.yebeh.2008.11.012. Epub 2008 Dec 25.
引用本文的文献
1
A highlight on carbamazepine-induced adverse drug reactions in Saudi Arabia: a retrospective medical records-based study.
Naunyn Schmiedebergs Arch Pharmacol. 2023 Nov;396(11):3177-3182. doi: 10.1007/s00210-023-02525-2. Epub 2023 May 18.
2
Deproteinization as a Rapid Method of Saliva Purification for the Determination of Carbamazepine and Carbamazepine-10,11 Epoxide.
J Clin Med. 2020 Mar 27;9(4):915. doi: 10.3390/jcm9040915.
3
The effects of fall-risk-increasing drugs on postural control: a literature review.
Drugs Aging. 2013 Nov;30(11):901-20. doi: 10.1007/s40266-013-0113-9.
4
Population pharmacokinetics of unbound and total drug concentrations following intravenously administered carbamazepine in elderly and younger adult patients with epilepsy.
J Clin Pharmacol. 2013 Mar;53(3):276-84. doi: 10.1002/jcph.8. Epub 2013 Feb 13.
5
Population pharmacokinetics of carbamazepine in elderly patients.
Ther Drug Monit. 2012 Apr;34(2):176-81. doi: 10.1097/FTD.0b013e31824d6a4e.
6
Treating epilepsy in the elderly: safety considerations.
Drug Saf. 2001;24(13):991-1015. doi: 10.2165/00002018-200124130-00006.
7
Anticonvulsant therapy in aged patients. Clinical pharmacokinetic considerations.
Drugs Aging. 1997 Apr;10(4):278-89. doi: 10.2165/00002512-199710040-00004.
8
Management of seizures in the elderly: a survey of UK geriatricians.
J R Soc Med. 1995 Dec;88(12):686-9. doi: 10.1177/014107689508801209.
9
Pharmacokinetic optimisation of drug therapy in elderly patients.
Drugs Aging. 1995 Jul;7(1):10-8. doi: 10.2165/00002512-199507010-00002.
10
Hepatic drug metabolism and aging.
Clin Pharmacokinet. 1990 Nov;19(5):359-89. doi: 10.2165/00003088-199019050-00002.
本文引用的文献
1
Concentrations and kinetics of carbamazepine in whole saliva, parotid saliva, serum ultrafiltrate, and serum.
Clin Pharmacol Ther. 1980 Nov;28(5):695-702. doi: 10.1038/clpt.1980.223.
2
Salivary concentrations and plasma protein binding of carbamazepine and carbamazepine 10,11-epoxide in epileptic patients.
Br J Clin Pharmacol. 1981 Jul;12(1):31-7. doi: 10.1111/j.1365-2125.1981.tb01851.x.
3
Saliva carbamazepine levels in children before and during multiple dosing.
Br J Clin Pharmacol. 1982 May;13(5):647-51. doi: 10.1111/j.1365-2125.1982.tb01431.x.
4
Psychomotor function and psychoactive drugs.
Br J Clin Pharmacol. 1980 Sep;10(3):189-209. doi: 10.1111/j.1365-2125.1980.tb01745.x.
5
Value of saliva samples in monitoring carbamazepine concentrations in epileptic patients.
Acta Neurol Scand. 1980 Jun;61(6):344-50. doi: 10.1111/j.1600-0404.1980.tb01503.x.
6
Drug disposition in the elderly: a review of the critical factors.
J Am Geriatr Soc. 1984 Feb;32(2):144-9. doi: 10.1111/j.1532-5415.1984.tb05856.x.
7
Distribution and elimination kinetics of carbamazepine in man.
Eur J Clin Pharmacol. 1975 Feb 28;8(2):91-6. doi: 10.1007/BF00561556.
Zotero 插件